AGM
NTLA icon

Alpine Global Management’s Intellia Therapeutics NTLA Stock Holding History

Alpine Global Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,935
Closed -$1.06M – 631
2021
Q4 		$1.06M Buy
+8,935
New +$1.12M 0.16% 135
2018
Q1 		– Sell
-10,000
Closed -$192K – 171
2017
Q4 		$192K Buy
+10,000
New +$231K 0.04% 131

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alpine Global Management's NTLA Position: Q1 2022 in Review

Alpine Global Management sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 8,935 shares — an estimated $1.06M sold.

Alpine Global Management first reported a position in NTLA in Q4 2017 and held it in 2 quarters. The position peaked at $1.06M in Q4 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Alpine Global Management reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 8,935 Intellia Therapeutics shares in Q1 2022, an estimated $1.06M.
  • Alpine Global Management first reported a position in Intellia Therapeutics in Q4 2017 and held it in 2 quarters.
  • Alpine Global Management's Intellia Therapeutics position peaked at $1.06M in Q4 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.